Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
PLD based chemotherapeutic regimen is a viable option for NAC of breast cancer. Epirubicin should be avoided for patients with mutations of some specific genes considering the potential severe AEs.
Authors
- Wei Jin (ORCID: https://orcid.org/0000-0001-8263-571X)
- Menghao Dong
- Kangsheng Gu (ORCID: https://orcid.org/0000-0002-5800-5256)
- Yuanyuan Shen (ORCID: https://orcid.org/0000-0003-2702-8073)
- X.C. Hu
- Qingling Hua
Institutions
- University of Science and Technology of China (CN)
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2024-12-23
- DOI
- https://doi.org/10.3389/fcell.2024.1448037
- Citations
- 3
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.86
Funders
- Anhui Medical University
- Anhui Provincial Department of Education